MAIA Biotechnology (NYSE: MAIA) Moves Approx 26% On Heels Of Breaking News Announcement

*Sponsored Market Crux Announces Its Next Potential Biotech Breakout  Idea For Tuesday! Consider Taking A Look At MAIA Biotechnology (NYSE: MAIA)  While It’s Still Early… Here’s Why We Have All Eyes on MAIA Biotechnology (NYSE: MAIA) Right Now. Analysts Target Up To 640% Upside Potential For (MAIA) With Bullish Calls From Noble Capital And Diamond Equity. With A Market Cap Under $48M, (MAIA)’s Limited Share Structure Has the Potential For Significant Swings If Demand Begins to Shift. FDA Grants THIO Orphan Designations For SCLC, HCC, And Glioblastoma, Highlighting Its Market Potential. Regeneron, A $76B Industry Giant, Expands Its Partnership With  (MAIA) For The THIO-101 Phase 2 Trial. Consider Adding MAIA Biotechnology (NYSE: MAIA) to Your Radar This Week. We Have All Eyes On (MAIA) In The Pre-Market…Consider Taking a Look While It’s Still Early… February 4, 2025 Dear Reader, Have you been watching MAIA Biotechnology (NYSE: MAIA) today? This morning, MAIA Biotechnology (NYSE: MAIA) dropped a bombshell that's making cancer cells quake in their metaphorical boots.  Have you been watching (MAIA) today? After its approximate 26% move, reaching $2.40 from yesterday’s $1.89 close, (MAIA) is currently trending near or over several key moving averages including: 5-Day: 1.9198 20-Day: 2.0205 50-Day: 2.0638 With its 100-Day moving average 2.3838 and 200-Day at 2.8317 we have all eyes on MAIA Biotechnology (NYSE: MAIA) right now.  Their powerhouse THIO is turning the tables on advanced non-small cell lung cancer (NSCLC) faster than you can say "remission." Patients who’ve failed two or more standard therapies are now seeing a median overall survival of 16.9 months—a jaw-dropping improvement over the typical 5 to 6 months seen with standard care.  It’s like THIO showed up to a knife fight with a flamethrower. Dr. Vlad Vitoc, MAIA’s CEO, is understandably hyped about these results, calling them a game-changer for third-line treatment where options are usually slim to none.   And with these findings bolstering their regulatory strategy, (MAIA) is eyeing accelerated FDA approval like it’s already in the bag. That’s exactly why MAIA Biotechnology (NYSE: MAIA) is on my radar today. This under-the-radar biotech is developing THIO, the only direct telomere-targeting anticancer agent in clinical development—something that could reshape the oncology space. And it’s not just me watching. Noble Capital Markets recently issued a $14.00 target, suggesting a potential upside of over 640% from Friday’s $1.89 open. Diamond Equity Research also weighed in, setting an $11.25 target, pointing to 495% potential upside. My name is Gary Silver, and I’m the Managing Editor of MarketCrux. For years, I’ve been dedicated to spotting small companies with massive potential before they explode onto Wall Street’s radar—and this one checks a lot of boxes. Between groundbreaking science, a small market cap, and a tight share structure, MAIA Biotechnology (NYSE: MAIA) could be positioned at the crossroads of breakthrough innovation and untapped potential. Why does that matter? While large-cap companies dominate headlines, small and micro-caps often offer far greater growth potential—especially when the right catalyst hits. With leaner operations, smaller revenue bases, and the ability to pivot quickly, these companies can scale rapidly when momentum shifts. Take MAIA Biotechnology (NYSE: MAIA)—with a market cap under $48M and fewer than 22M shares in the float, it has the kind of tight structure that has historically fueled explosive moves when demand changes. And here’s something else worth noting—insiders have been loading up. Since November 2024, four insiders have acquired over 300K shares. When breakthrough science meets a small-cap profile like this, the upside potential could be significant. MAIA Biotechnology (NYSE: MAIA) Takes Center Stage at  Biotech Showcase™ 2025 Dr. Vlad Vitoc Unveils Critical Updates on THIO-101 and the Future of Oncology Dr. Vlad Vitoc, CEO of MAIA Biotechnology (NYSE: MAIA), recently took the stage at Biotech Showcase™ 2025, one of the industry’s most closely watched events. During his presentation, he provided key updates on the THIO-101 Phase 2 trial expansion, which focuses on advanced non-small cell lung cancer (NSCLC) patients receiving third-line (3L) therapy. He also outlined (MAIA)’s plans for upcoming trials targeting multiple high-value cancer indications, highlighting the company’s continued push toward innovative oncology treatments. If you haven’t heard of MAIA Biotechnology (NYSE: MAIA) yet, consider this your wake-up call.  Targeting a $34B Market: MAIA’s THIO Delivers Unprecedented  Results in NSCLC  Patients See Sustained Remission and No Cancer Recurrence MAIA Biotechnology (NYSE: MAIA) lead asset, THIO (6-thio-dG), is the first and only telomere-targeting agent in clinical development.  THIO operates with a dual mechanism of action (MoA): directly targeting telomeres to disrupt cancer cell replication while simultaneously activating an immune response to destroy the cancer cells. The Phase 2 THIO-101 trial focuses on non-small cell lung cancer (NSCLC), a market worth a staggering $34B annually.  Results? Nothing short of groundbreaking.  THIO followed by immune checkpoint inhibitors (ICIs) like Regeneron’s Libtayo® has demonstrated 60% complete response rates in preclinical models.  Patients achieved sustained remission after just two cycles of therapy, with no cancer recurrence—even after rechallenge with 5x the initial cancer cell load.  This isn’t just a treatment—it’s a potential revolution. FDA Grants THIO Orphan Designations—A Major Milestone Small Cell Lung Cancer, Liver Cancer, and Brain Cancer Now in Focus The fight against cancer is an intense battleground, and (MAIA) is positioning itself for a game-changing win. NSCLC is the largest cancer market globally, and THIO is positioned to address patients who have become resistant to current checkpoint inhibitors—an enormous unmet need.  The U.S. FDA has already recognized THIO’s promise, granting Orphan Designations for small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), and glioblastoma (brain cancer). Let’s talk numbers: NSCLC: $34B annual sales. Checkpoint Inhibitors: $46B global market in 2023, with Keytruda alone generating $9B in NSCLC sales. HCC and SCLC: Combined annual sales of $5B with massive growth potential. MAIA Biotechnology (NYSE: MAIA) owns worldwide rights to THIO, securing the company’s stake in every dollar these markets generate. THIO-101 Raises the Bar—85% DCR and a 38% Objective Response Rate in 3L Cancer Patients 85% DCR, nearly double median survival—this is more than just a treatment, it’s a breakthrough. The THIO-101 trial has set a new standard for cancer therapies. Patients treated with THIO + Libtayo® showed a disease control rate (DCR) of 85%, far surpassing the 25–35% DCR achieved by traditional chemotherapy.  Even in third-line (3L) settings—where options are typically grim—THIO delivered unprecedented outcomes: Median progression-free survival (PFS): 2.5 months (compared to 1.5 months with chemotherapy). Median overall survival (OS): 5.8 months (nearly double the historical benchmark). Objective response rate (ORR): 38%, a dramatic leap from the 6–10% seen with chemotherapy. These results underscore one thing: THIO is not just effective; it’s transformative. Pipeline Expansion in Motion: (MAIA) Sets Its Sights Beyond NSCLC (MAIA) isn’t stopping at NSCLC. With a robust pipeline of trials planned for colorectal cancer (CRC), SCLC, HCC, and other solid tumors, the company is poised to address multiple high-value cancer indications.  Interestingly, preclinical models in CRC demonstrated a 100% complete response rate with long-term immune memory formation. The strategy?  Expand THIO’s applications while leveraging collaborations with big pharma players like Regeneron.   A $76B Industry Giant Backs MAIA’s Lead Therapy—Here’s Why It Matters Around 2 months ago, on December 3, 2024, MAIA Biotechnology (NYSE: MAIA) announced the expansion of its clinical supply agreement with Regeneron, a +$76B industry leader, for the ongoing Phase 2 THIO-101 trial.  This partnership focuses on evaluating (MAIA)'s lead asset, THIO, in combination with Regeneron’s Libtayo® (cemiplimab), an immune checkpoint inhibitor.  The trial targets advanced non-small cell lung cancer (NSCLC) patients resistant to prior checkpoint inhibitor therapies and chemotherapy. Initially signed in 2021, the agreement was designed to supply Libtayo® during the dose selection and safety evaluation stages.  The expanded agreement now supports a broader patient population to assess THIO’s efficacy at the optimal dose. Regeneron provides Libtayo® for all trial patients, while MAIA sponsors the study and retains exclusive global rights to develop and commercialize THIO. This collaboration highlights Regeneron's confidence in THIO’s potential to enhance checkpoint inhibitor outcomes.  With THIO demonstrating promising disease control, progression-free survival, and overall response rates, MAIA Biotechnology (NYSE: MAIA) is advancing its regulatory pathway and exploring the potential for accelerated U.S. approval based on trial results.  Beyond the expansion of THIO-101, the company is systematically building a robust pipeline of Phase 2/3 trials, including THIO-102 (targeting CRC, HCC, and SCLC) and THIO-103 (first-line NSCLC).  Together, these initiatives position MAIA as a biotech powerhouse with a portfolio designed for long-term growth. Strong IP, Experienced Team—Could (MAIA) Have What It Takes to Transform Oncology (MAIA)’s intellectual property portfolio is as robust as its science. The company holds five issued patents and 29 pending applications covering telomere-targeting compounds and THIO’s immunogenic treatment strategy.  With exclusivity agreements extending to 2041, MAIA is ensuring its technology remains unrivaled for decades. Leadership: Experience That Delivers MAIA Biotechnology (NYSE: MAIA)’s team brings over 70 years of combined experience in oncology and biotech.  CEO Dr. Vlad Vitoc has led the launch of 12 oncology compounds across 20 tumor types, while CSO Dr. Sergei Gryaznov—the co-inventor of THIO—is a global authority on telomeres and cancer.  This isn’t their first rodeo, and it shows. MAIA Biotechnology (NYSE: MAIA) is not just another biotech company. It’s a disruptor, a trailblazer, and quite possibly the future of cancer treatment.  With a pipeline brimming with potential, collaborations with leading industry players, and a market valued in the high ranges, (MAIA) stands out as a company to keep on your radar. In the fight against cancer, (MAIA) is bringing the big guns.  And if their data is anything to go by, this is one company to keep an eye on. 5 Things to Know About MAIA Biotechnology (NYSE: MAIA)  While It’s Still Early 1. Analysts Are Taking Notice: Noble Capital Markets has set a $14.00 target on (MAIA), suggesting 640% upside potential, while Diamond Equity Research pins a $11.25 target on them. With a market cap under $48M and fewer than 22M shares in the float, (MAIA) has a structure that could see significant movement if demand shifts. Insiders have also acquired over 300K shares since November 2024. 2. A Game-Changer in Cancer Treatment: THIO is the first and only direct telomere-targeting anticancer agent in clinical development, setting (MAIA) apart in the oncology space. The U.S. FDA has recognized THIO’s potential, granting Orphan Designations for small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), and glioblastoma. 3. A $76B Industry Giant In Their Corner: Regeneron, a major biotech leader, expanded its clinical supply agreement with (MAIA) for the THIO-101 Phase 2 trial, reinforcing confidence in THIO’s ability to enhance checkpoint inhibitors. This partnership highlights the credibility of (MAIA)'s technology in the biotech industry. 4. Breakthrough Clinical Results:  The THIO-101 trial has delivered an 85% disease control rate and a 38% objective response rate, significantly outperforming traditional late-stage cancer treatments. Patients have also shown nearly double the median survival rates compared to chemotherapy, reinforcing THIO’s potential impact in oncology. 5. Expanding Pipeline: Beyond NSCLC, (MAIA) is advancing multiple Phase 2/3 trials targeting colorectal cancer, liver cancer, and small cell lung cancer. With exposure to high value oncology markets and continued pipeline expansion, (MAIA) is positioning itself for long-term growth in the biotech space. With FDA Recognition & Regeneron Backing, MAIA (NYSE: MAIA) Is On Our Radar… MAIA Biotechnology (NYSE: MAIA) is making its mark in the biotech space with a groundbreaking approach to cancer treatment and growing industry recognition. Analysts have set ambitious targets, and with its small market cap and limited share structure, any shift in demand could have the potential for significant swings.  THIO’s impressive clinical results, FDA Orphan Designations, and partnership with Regeneron highlight its potential to reshape oncology treatments. With multiple Phase 2/3 trials in progress and expansion into high-value cancer markets, (MAIA) is positioning itself as one to watch closely. MAIA Biotechnology (NYSE: MAIA) moved approximately 26%, reaching $2.40 from yesterday’s $1.89 close, and is currently trending near or over several key moving averages. Are you watching (MAIA) right now?  Watch for my next update. Sincerely, Gary Silver Managing Editor, MarketCrux MarketCrux.com (“MarketCrux” or “MC” ) is owned by Headline Media LLC, a multi member limited liability company. Data is provided from third-party sources and MarketCrux is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MC brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owners of Headline Media LLC own and operate marketcrux . com (“MC”). From time to time, MC will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: marketcrux.com/disclaimer/  *Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired by TD Media LLC for a period beginning on 02/03/2025 and ending on 02/04/2025 to publicly disseminate information about (MAIA:US) via digital communications. Under this agreement, Headline Media LLC has been paid seven thousand five hundred USD (“Funds”) to disseminate information about (MAIA:US) via digital communications. To date, including under the previously described agreement, Headline Media LLC has been paid fifteen thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the funds from the issuer and does not own stock in the issuer but the reader should assume that the clients of the third party own shares in the issuer that they will liquidate at or near the time you receive this communication, which has the potential to hurt share prices. Neither Headline Media LLC, TD Media LLC or their members own shares of (MAIA:US). Please see important disclosure information here: https://marketcrux.com/disclosure/maia/#details

Headline Media | 7901 4th Street N Suite 300 | St. Petersburg, FL 33702 US Unsubscribe | Update Profile | Constant Contact Data Notice